Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety Results of a randomized, placebo-controlled study

1. Kavanaugh, A.
2. Mclnnes, I.
3. Mease, P.
4. Krueger, G.G.
5. Gladman, D.
6. Gomez-Reino, J.
7. Papp, K.
8. Zrubek, J.
9. Mudivarthy, S.
10. Mack, M.
11. Visvanathan, S.
12. Beutler, A.